Skip to content

Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors

Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06624865
Acronym
Microbio-siNET
Enrollment
75
Registered
2024-10-03
Start date
2024-11-05
Completion date
2029-10-31
Last updated
2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small-intestine Neuroendocrine Tumors

Keywords

Small-intestine neuroendocrine tumor, microbiota, tumorigenesis

Brief summary

The aim of the study is to investigate the impact of the microenvironment on tumorigenesis of small intestinal neuroendocrine tumors often located in the terminal ileum, without identified driver mutations.

Interventions

OTHERBlood and stool sampling

Blood and stool sampling

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with one or more small-intestine neuroendocrine tumor with indication of surgery * Patient with consent for the collection, storage and reuse of data associated with his/her disease * Age ≥ 18 years at the time of inclusion * Non-objection statement obtained for participation in the study

Exclusion criteria

* Patients with poorly differentiated neuroendocrine carcinoma or NET (neuroendocrine tumors) of non-intestinal origin or mixed tumors (MiNEN) * Pregnant, parturient or breast-feeding women * Minors * Persons deprived of liberty by judicial or administrative decision * Adults under legal protection (guardianship, curatorship)

Design outcomes

Primary

MeasureTime frameDescription
Composition of microbiotaAt day 1 and month 3Determination of the composition of blood, fecal, intra- and peri-tumoral microbiota in patients undergoing surgery for small-intestine neuroendocrine tumor.

Countries

France

Contacts

Primary ContactThomas WALTER, MD, PhD
thomas.walter@chu-lyon.fr0472117398

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026